In the first quarter of 2024, the Company initiated a restructuring program to improve profitability and to respond to changes in its markets. The program, authorized in 2021, allows for charges of $50.0 million to $100.0 million, and does not have pre-determined actions or a specified time period.

During the first quarter of 2024, the Company committed to a plan to cease commercialization and clinical development, and wind down production of StrataGraft®, included in the Specialty Brands segment, which was completed in the first quarter of 2025.

Net restructuring and related (credits) charges by segment were as follows:


	Three Months Ended
	March 28, 2025		March 29, 2024
Specialty Brands	$	(2.0)	$	10.2

Net restructuring and related (credits) charges by program were comprised of the following:


	Three Months Ended
	March 28, 2025		March 29, 2024
2021 Program	$	(2.0)	$	10.2

The following table summarizes the restructuring reserves, which are included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets:


	2021 Program
	Severance		Contract Costs		Total
Balance as of December 27, 2024	$	0.2	$	1.1	$	1.3

Changes in estimate from continuing operations	—		(2.0)		(2.0)
Cash received	—		0.9		0.9
Balance as of March 28, 2025	$	0.2	$	—	$	0.2

Cumulative net restructuring and related charges incurred for the 2021 program was as follows as of March 28, 2025: